Pillartree Limited, a new subsidiary of Amgen, has struck a deal to acquire Horizon Therapeutics, which markets Uplizna (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD). Last month, Horizon announced that it was in preliminary discussions about a potential sale to three pharmaceutical companies — Amgen,…
Uplizna
Among people with neuromyelitis optica spectrum disorder (NMOSD) who started treatment with Uplizna (inebilizumab-cdon) in a clinical trial, an early and strong reduction in B-cell counts was associated with a quicker decline in disease activity. This report comes from an analysis of data from the Phase 2/3…
Treatment with Uplizna (inebilizumab-cdon) can reduce levels of antibodies that drive neuromyelitis optica spectrum disorder (NMOSD), new clinical trial data show. The data also show that, among patients who aren’t on Uplizna, NMOSD attacks are often preceded by a sharp rise in levels of disease-driving antibodies and/or antibody-producing…
Uplizna (inebilizumab-cdon) was found effective both at reducing attacks and lessening disability in people with neuromyelitis optica spectrum disorder (NMOSD) living in Europe, according to data from the N-MOmentum Phase 2/3 trial. Nearly 90% of participants given Uplizna remained free from attacks six months after starting the therapy,…
Uplizna (inebilizumab-cdon) works to treat people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether such patients carry genetic variants linked to poor responses to other B-cell depleting therapies, new trial data show. An analysis of N-MOmentum Phase 2/3 data found that the approved therapy was as effective…
The European Commission has approved Uplizna (inebilizumab-cdon) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4-IgG). The approval covers all member states in the European Union, as well as Iceland, Liechtenstein, and Norway. Horizon Therapeutics, the company marketing Uplizna,…
Uplizna (inebilizumab-cdon) was just as safe and effective in people with neuromyelitis optica spectrum disorder (NMOSD) treated after only one symptomatic attack as those treated after two or more attacks, according to an analysis of N-MOmentum Phase 2/3 trial data. This sub-analysis had sought to understand how a…
Blood levels of two proteins, GFAP and neurofilament light chain (NfL), may help predict the course of neuromyelitis optica spectrum disorder (NMOSD), according to new research. Findings also suggest that many NMOSD patients have evidence of brain lesions with active inflammation without any associated symptoms, which indicates that disease…
Uplizna (inebilizumab-cdon) effectively reduced the severity of attacks in people with neuromyelitis optica spectrum disorder (NMOSD) who continued to experience attacks after being treated with the therapy during the N-MOmentum Phase 2/3 clinical trial, recent data analysis shows. The data also demonstrated lower levels of key disease-related biomarkers,…
Prior treatment with rituximab does not limit the effectiveness or safety of Uplizna (inebilizumab-cdon) in people with  neuromyelitis optica spectrum disorder (NMOSD), a further analysis of data from the N-MOmentum Phase 2/3 trial has found. Uplizna’s efficacy in preventing NMOSD attacks and its safety profile were comparable in trial…
Recent Posts
- New biomarker may help gauge disease severity in NMOSD
- The longest night of the year offers hope of brighter days with NMOSD
- Advanced plasma exchange therapy effectively eases NMOSD attacks
- Reaffirming that access to healthcare is a human right
- Brain, spinal cord shrinkage linked to distinct NMOSD outcomes: Study
- Reflecting on what I’m grateful for softens the edges of NMOSD
- When my invisible illness meets my very visible disabled parking spot
- Study IDs environmental factors tied globally to higher NMOSD risk
- Inflammatory protein S100A9 ID’d as new treatment target in NMOSD
- Connecting with others who have NMOSD gave me hope